116
Views
3
CrossRef citations to date
0
Altmetric
Antimicrobial Original Research Paper

Can low-dose preemptive valganciclovir replace standard intravenous ganciclovir treatment in recipients of allogeneic stem cell transplantation?

, , , , , , , , , , & show all
Pages 286-291 | Published online: 18 Nov 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Enrico Maffini, Luisa Giaccone, Moreno Festuccia, Lucia Brunello, Alessandro Busca & Benedetto Bruno. (2016) Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation. Expert Review of Hematology 9:6, pages 585-596.
Read now

Articles from other publishers (2)

M. Takahata, S. Hashino, M. Nishio, J. Sugita, A. Shigematsu, M. Onozawa, K. Fujimoto, T. Endo, T. Kondo, J. Tanaka, M. Imamura & T. Teshima. (2015) Occurrence of adverse events caused by valganciclovir as pre-emptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low-dose administration. Transplant Infectious Disease 17:6, pages 810-815.
Crossref
Natalia Maximova, Pizzol Antonio, Granzotto Marilena, Francesca Rovere & Paolo Tamaro. (2015) Complete remission of VZV reactivation treated with valganciclovir in a patient with total lymphocyte depletion and acute kidney injury after allogeneic bone marrow transplantation. APMIS 123:1, pages 77-80.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.